Related Experiment Video
Updated: Jun 21, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice
Masanori Ookubo1, Hironori Yokoyama, Hiroyuki Kato
1Department of Neurobiology and Therapeutics, Graduate School and Faculty of Pharmaceutical Sciences, The University of Tokushima, 1-78, Sho-machi, Tokushima 770-8505, Japan.
Abstract:
The aim of this study was to investigate the impact of gender difference in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated animal model of Parkinson's disease (PD). In the present study, we investigated the time-dependent alterations of dopamine and its metabolites, striatal tyrosine hydroxylase (TH) protein, dopamine transporter (DAT) protein, glial fibrillary acidic protein (GFAP) protein and midbrain TH protein and motor function in male and female mice 5h and 1, 3 and 7 days after four administrations of MPTP (20mg/kg) at 2-h intervals. The present study showed that the decrease of dopamine, DOPAC (3,4-dihydroxyphenylacetic acid) and HVA (homovanillic acid) content in female mice was more pronounced than that in male animals 1, 3 and 7 days after MPTP treatment. Our Western blot analysis study also demonstrated that the decrease of both striatal and midbrain TH protein levels in female mice was more pronounced than that in male animals from 1 to 7 days after MPTP treatment. As compared to male mice, in contrast, the increase of striatal GFAP protein levels in female mice was observed from 5h to 7 days after MPTP treatment. Furthermore, the present study showed that motor deficits were found in both male and female mice 1 and 7 days after MPTP treatment. In the present study, moreover, the decrease of striatal DAT protein levels in female mice was more pronounced than that in male animals 1, 3 and 7 days after MPTP treatment. These results demonstrate that our administrations of MPTP at 2-h intervals can cause more severe damage in female mice as compared with male animals. The gender difference may be due to the decrease of DAT expression caused by MPTP. Thus our findings provide further valuable information for the pathogenesis of PD.
Insights
Female mice exhibit more severe Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
- The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model is widely used to study PD pathogenesis.
- Understanding gender-specific differences in PD progression is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the impact of gender on MPTP-induced neurodegeneration in a mouse model of Parkinson's disease.
- To analyze time-dependent alterations in dopamine levels, protein expression, and motor function between male and female mice.
- To explore the role of dopamine transporter (DAT) expression in observed gender differences.
Main Methods:
- Male and female mice were administered MPTP (20mg/kg) at 2-hour intervals.
- Dopamine and its metabolites, striatal and midbrain tyrosine hydroxylase (TH), dopamine transporter (DAT), and glial fibrillary acidic protein (GFAP) levels were measured.
- Motor function was assessed at various time points (5h, 1, 3, and 7 days) post-MPTP administration.
Main Results:
- Female mice showed more pronounced decreases in dopamine, DOPAC, and HVA compared to male mice.
- Striatal and midbrain TH protein levels were significantly reduced in female mice post-MPTP treatment.
- MPTP treatment led to a greater decrease in striatal DAT protein levels and a more pronounced increase in GFAP in female mice.
Conclusions:
- MPTP administration causes more severe neurotoxicity and motor deficits in female mice compared to male mice.
- Reduced dopamine transporter (DAT) expression in females may contribute to the observed gender-specific vulnerability.
- These findings highlight the importance of gender in PD pathogenesis and suggest potential therapeutic targets.
